One of the final steps in the pathology of non-alcoholic steatohepatitis (NASH) is oxidative damage to hepatocytes.
Probucol is a lipid-lowering agent with strong antioxidant properties.
In this study, researchers from Iran used a double-blind randomized controlled design to evaluate the effects of probucol in NASH.
The research team included 30 cases of biopsy-proven NASH.
| AST and ALT fell to normal levels in 50% of the treatment group.|
|Journal of Hepatology|
They randomly allocated subjects to either the treatment group or the control group.
The team gave the treatment group 500mg of probucol daily for 6 months, while the control group received placebo.
Overall, 27 patients completed the study.
The researchers found that the mean aspartate transaminase (AST) levels changed from 81.9 to 36.2 in the treatment group, and from 57.6 to 49.6 in the control.
In addition, alanine transaminase (ALT) levels changed from 102.2 to 44.7 in the treatment group, and from 96.8 to 96.2 in the control group.
The team determined that there was a significant decrease in ALT levels in the treatment group, compared to the control.
Furthermore, AST and ALT fell to normal levels in 50% of the treatment group, but in none of the control group.
Dr Shahin Merat’s team concluded, “Probucol appears to be significantly effective in decreasing the ALT levels in patients with NASH”.